Additional studies are required to elucidate the relevance of apparently contradictory effects produced by certain semaphorins, such as Sema3A, in different GBM experimental settings, and better delineate their actual implications in the future of GBM therapy. This evidence concerns the gene SEMA3A and glioblastoma.